Sight Sciences, Inc. filed a Form 8-K with the SEC on November 4, 2026, reporting its financial results for the quarter ended September 30, 2026, and announcing an upward revision to its full-year 2026 revenue guidance.

Key Highlights

  • Quarterly results disclosed: The company issued a press release on November 4, 2026, covering financial results for the quarter ended September 30, 2026.
  • Revenue guidance raised: According to the filing, the company raised its revenue guidance for the year ending December 31, 2026.
  • Investor presentation posted: An investor presentation was made available on November 4, 2026, furnished as Exhibit 99.2.
  • Emerging growth company status: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
  • Signed by CFO: The report was signed by James Rodberg, Chief Financial Officer and Principal Financial and Accounting Officer.

Sight Sciences Reports Third-Quarter 2026 Financial Results and Revises Full-Year Outlook

Sight Sciences, Inc. (NASDAQ:SGHT), a Delaware-incorporated ophthalmology company headquartered at 4040 Campbell Avenue, Suite 100, Menlo Park, California 94025, filed a current report on November 4, 2026, covering two disclosure items. Under Item 2.02, the company reported results of operations and financial condition for the quarter ended September 30, 2026, through a press release furnished as Exhibit 99.1. That same press release, according to the filing, also contained an upward revision to revenue guidance for the full year ending December 31, 2026.

Under Item 7.01, the company disclosed that it posted an investor presentation on November 4, 2026, furnished as Exhibit 99.2. The filing states the company "expects to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others." Both the earnings press release and the investor presentation are furnished, not filed, meaning they are not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as the registrant expressly noted in the filing.

The common stock of Sight Sciences carries a par value of $0.001 per share and is listed on the Nasdaq Global Select Market under the trading symbol SGHT. The company holds Commission File Number 001-40587 and IRS Employer Identification Number 80-0625749. James Rodberg, in his capacity as Chief Financial Officer and Principal Financial and Accounting Officer, signed the report on behalf of the registrant on November 4, 2026.

What Was Disclosed

Sight Sciences filed an 8-K on November 4, 2026, furnishing its Q3 2026 earnings press release and an investor presentation as exhibits, and disclosing a raise to its full-year 2026 revenue guidance. The filing was signed by CFO James Rodberg.